Sandra will talk at this session about the state of the healthcare industry, which broadly encompasses any tool, service or product with which a patient may interact to seek a diagnosis or treatment, and the opportunity exists to bring technologies that are currently in adoption mode in other industries (tech, gaming) into healthcare.
Healthcare follows when it comes to tech adoption; it doesn’t lead. This presents the opportunity to take proven successful technologies adopted in other industries and bring them to healthcare in customized ways. It also presents the opportunity to find new technologies that increase the efficiency of the healthcare system. In this talk you’ll learn about:
- Healthcare as follower
- Buyer types and influence
- B2B business models that work
As well as: Exit Strategy – Making the most of a once in a lifetime opportunity to sell your business; Mindful startup – Key lessons for periods of high output and creativity.
More about Sandra:
Ms. Shpilberg is the Founder of Seeker Health. Headquartered in Palo Alto, CA, Seeker Health offers breakthrough digital patient identification technology to accelerate drug development and commercialization for biopharmaceutical companies. Since starting the company in 2015, Ms. Shpilberg developed a breakthrough software product, filed a US patent, and built a team which serves 40+ biopharmaceutical companies to accelerate clinical trial enrollment in rare diseases and oncology. During this time, the revenue of Seeker Health doubled each year and profit tripled. In September 2018, EVERSANA the leading independent provider of global services to the life science industry acquired Seeker Health, in an all cash deal. Ms. Shpilberg continues to lead the company.
Prior to this successful entrepreneurial pursuit, Ms. Shpilberg held executive roles at biopharmaceutical companies. She served as Vice President of Commercial Development and Strategic Marketing for Nora Therapeutics, and as Executive Director at BioMarin Pharmaceutical where she led the commercial launches of NAGLAZYME and KUVAN, and advanced PALINZIQ from Phase 2 to Phase 3.
Medical Marketing & Media named her a Top 40 Healthcare Transformer, and she was a featured speaker at 2018 SXSW. She’s originally from Uruguay, speaks fluent Spanish, and brings a global approach to her work and impact. She holds an MBA in Marketing and Entrepreneurial Management from The Wharton School at the University of Pennsylvania.
Date: Thursday, July 18, 2019
Time: 6:30pm – 8:30pm
Location: 2479 E. Bayshore Drive, Suite 100, Palo Alto, CA 94303